CASE REPORT article
Front. Pediatr.
Sec. Pediatric Oncology
Maxillary Mesenchymal Chondrosarcoma Harboring HEY1::NCOA2 Fusion in a 13-Year-Old Girl: A Rare Case Report and Literature Review
Provisionally accepted
- Adana City Training and Research Hospital, Ministry of Health (Turkey), Adana, Türkiye
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Mesenchymal chondrosarcoma (MCS) is a rare and highly aggressive subtype of chondrosarcoma, accounting for less than 1% of all chondrosarcomas. It predominantly affects adolescents and young adults and frequently arises in craniofacial bones and soft tissues. Diagnosis is challenging because of significant histological overlap with other high-grade spindle cell sarcomas, particularly when the cartilaginous component is minimal or absent. The identification of the HEY1::NCOA2 gene fusion has emerged as a highly specific molecular marker for MCS, substantially improving diagnostic accuracy and providing potential therapeutic implications. Case Presentation: We report the case of a 13-year-old girl who presented with a 3-month history of progressive right cheek swelling. Imaging revealed a destructive mass in the right maxillary sinus. Histopathological evaluation demonstrated a high-grade spindle cell tumor, initially interpreted as fibrosarcoma, showing diffuse vimentin positivity, a high Ki-67 proliferation index (35–40%), and CD34 negativity. Comprehensive molecular analysis confirmed a pathogenic HEY1::NCOA2 gene fusion, while ETV6::NTRK3 fusion was excluded. The patient was treated with VAC chemotherapy (vincristine, actinomycin D, cyclophosphamide), local radiotherapy (60 Gy), cranial prophylactic radiotherapy (12 Gy), and subsequent debulking surgery. Follow-up 18F-FDG PET/CT demonstrated a partial metabolic response. Given persistent disease and molecular evidence suggesting activation of the PI3K/AKT/mTOR pathway in MCS, maintenance therapy with the mTOR inhibitor sirolimus was initiated. Conclusion: This case highlights the pivotal role of molecular diagnostics—particularly RNA sequencing—in establishing the diagnosis of mesenchymal chondrosarcoma and differentiating it from other high-grade pediatric sarcomas with overlapping morphology. Identification of the HEY1::NCOA2 fusion not only confirms the diagnosis but may also support biologically targeted therapeutic strategies. Multimodal treatment incorporating chemotherapy, radiotherapy, surgery, and targeted maintenance therapy can achieve meaningful disease control in aggressive craniofacial MCS. To our knowledge, this represents one of the very few reported pediatric cases of maxillary MCS with confirmed HEY1::NCOA2 fusion managed with sirolimus-based maintenance therapy.
Keywords: HEY1::NCOA2 fusion, Maxillary sinus tumor, Mesenchymal chondrosarcoma, pediatric sarcoma, RNA sequencing, Sirolimus, targeted therapy
Received: 01 Dec 2025; Accepted: 10 Feb 2026.
Copyright: © 2026 Çalışkan Kamış, Yağcı, Koç, Durak and Yitik. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Şule Çalışkan Kamış
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.